Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Hee-Jun Kim, Yong Bae Kim, Jee Suk Chang, Jee Hyun Kim, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki Chung, Kyung Su Kim, Ji Ho Nam, Won Sup Yoon, Jin Hee Kim, Jihye Cha, Yoon Kyeong Oh, In Ah Kim
Cancer Res Treat. 2022;54(4):1121-1129. Published online December 31, 2021
Purpose We aimed to investigate manifestations and patterns of care for patients with brain metastasis (BM) from breast cancer (BC) and compared their overall survival (OS) from 2005 through 2014 in Korea.
Materials and Methods We retrospectively reviewed 600 BC patients with BM diagnosed between 2005 and 2014. The median follow-up duration was 12.5 months. We categorized the patients into three groups according to the year when BM was initially diagnosed (group I [2005-2008], 98 patients; group II [2009-2011], 200 patients; and group III [2012-2014], 302 patients).
Results Over time, the median age at BM diagnosis increased by 2.2 years (group I, 49.0 years; group II, 48.3 years; and group III, 51.2 years; p=0.008). The percentage of patients with extracranial metastasis was 73.5%, 83.5%, and 86.4% for group I, II, and III, respectively (p=0.011). The time interval between BC and BM was prolonged in patients with stage III primary BC (median, 2.4 to 3 years; p=0.029). As an initial brain-directed treatment, whole-brain radiotherapy alone decreased from 80.0% in 2005 to 41.1% in 2014. Meanwhile, stereotactic radiosurgery or fractionated stereotactic radiotherapy alone increased from 13.3% to 34.7% during the same period (p=0.005). The median OS for group I, II, and III was 15.6, 17.9, and 15.0 months, respectively, with no statistical significance.
Conclusion The manifestations of BM from BC and the pattern of care have changed from 2005 to 2014 in Korea. However, the OS has remained relatively unchanged over the 10 years.
Citations
Citations to this article as recorded by
Comparison of initial and sequential salvage brain-directed treatment in patients with 1–4 vs. 5–10 brain metastases from breast cancer (KROG 16–12) Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Hee-Jun Kim, Yong Bae Kim, Jee Suk Chang, Jee Hyun Kim, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki C Breast Cancer Research and Treatment.2023; 200(1): 37. CrossRef
Hee Yeon Lee, Ji Hyung Hong, Jae Ho Byun, Hee-Jun Kim, Sun Kyung Baek, Jin Young Kim, Ki Hyang Kim, Jina Yun, Jung A Kim, Kwonoh Park, Hyo Jin Lee, Jung Lim Lee, Young-Woong Won, Il Hwan Kim, Woo Kyun Bae, Kyong Hwa Park, Der-Sheng Sun, Suee Lee, Min-Young Lee, Guk Jin Lee, Sook Hee Hong, Yun Hwa Jung, Ho Jung An
Cancer Res Treat. 2020;52(1):277-283. Published online July 12, 2019
Purpose
The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early
stage.
Materials and Methods
Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected.
Results
Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease ≤ 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence.
Conclusion
Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required.
Citations
Citations to this article as recorded by
Ovarian clear cell carcinoma: open questions on the management and treatment algorithm Roberta Rosso, Margherita Turinetto, Fulvio Borella, Nicolas Chopin, Pierre Meeus, Alexandra Lainè, Isabelle Ray-Coquard, Olivia Le Saux, Domenico Ferraioli The Oncologist.2025;[Epub] CrossRef
From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer Zesi Liu, Chunli Jing, Fandou Kong Journal of Ovarian Research.2024;[Epub] CrossRef
Construction of a Prediction Model of Cancer-Specific Survival after Ovarian Clear Cell Carcinoma Surgery Mengqi Huang, Li Ling, Yanbo Liu, Yujuan Li Clinical and Experimental Obstetrics & Gynecology.2024;[Epub] CrossRef
Patients with stage IA ovarian clear cell carcinoma do not require chemotherapy following surgery Li Shuqing, Zhu Zhiling Cancer Medicine.2023; 12(6): 6668. CrossRef
Clear cell carcinoma of the ovary and venous thromboembolism: a systematic review and meta-analysis Hamidreza Didar, Farah Farzaneh, Hanieh Najafiarab, Kosar Namakin, Kimiya Gohari, Ali Sheidaei, Sepehr Ramezani Current Medical Research and Opinion.2023; 39(6): 901. CrossRef
The Significance of Radiotherapy in Ovarian Clear Cell Carcinoma: A Systematic Review and Meta-Analysis Yuan Zhuang, Hua Yang Cancer Control.2023;[Epub] CrossRef
Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer Satoe Fujiwara Japanese Journal of Clinical Oncology.2023; 53(8): 664. CrossRef
Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience Yoo-Na Kim, Yun Soo Chung, Ji Hyun Lee, Eunhyang Park, Seung-Tae Lee, Sunghoon Kim, Jung-Yun Lee Journal of Gynecologic Oncology.2023;[Epub] CrossRef
Characteristics and Prognosis of Ovarian Pure Clear Cell Carcinoma: A Retrospective Experience of 136 Patients Yang Gao, Wei Ding, Pengpeng Qu Clinical and Experimental Obstetrics & Gynecology.2023;[Epub] CrossRef
A clearer view on ovarian clear cell carcinoma Aglaja De Pauw, Eline Naert, Koen Van de Vijver, Tummers Philippe, Katrien Vandecasteele, Hannelore Denys Acta Clinica Belgica.2022; 77(4): 792. CrossRef
Friend or foe? The prognostic role of endometriosis in women with clear cell ovarian carcinoma. A UK population-based cohort study Anastasios Tranoulis, Felicia Helena Buruiana, Bindiya Gupta, Audrey Kwong, Aarti Lakhiani, Jason Yap, Janos Balega, Kavita Singh Archives of Gynecology and Obstetrics.2022; 305(5): 1279. CrossRef
Association Between Endometriosis and Prognosis of Ovarian Cancer: An Updated Meta-Analysis Peng Chen, Chi-Yuan Zhang Frontiers in Oncology.2022;[Epub] CrossRef
Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report Abdulkarim Mohamed Farah, Shiyu Gu, Yan Jia Medicine.2022; 101(37): e30666. CrossRef
Clear cell carcinoma of the ovary: a clinical and molecular perspective Yasushi Iida, Aikou Okamoto, Robert L Hollis, Charlie Gourley, C Simon Herrington International Journal of Gynecological Cancer.2021; 31(4): 605. CrossRef
Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study Chenchen Zhu, Jing Zhu, Lili Qian, Hanyuan Liu, Zhen Shen, Dabao Wu, Weidong Zhao, Weihua Xiao, Ying Zhou BMC Cancer.2021;[Epub] CrossRef
The oncological outcome of the patients with ovarian clear cell cancer: Platinum-based adjuvant chemotherapy is not suitable Caner ÇAKIR, Fatih KILIÇ, Çiğdem KILIÇ, Dilek YÜKSEL, Vakkas KORKMAZ, Günsu KİMYON CÖMERT, Osman TÜRKMEN, Taner TURAN Journal of Surgery and Medicine.2021; 5(8): 1. CrossRef
Development and validation of Nomograms for predicting overall survival and Cancer-specific survival in patients with ovarian clear cell carcinoma Qian Chen, Shu Wang, Jing-He Lang Journal of Ovarian Research.2020;[Epub] CrossRef
In Hae Park, Seock-Ah Im, Kyung Hae Jung, Joo Hyuk Sohn, Yeon Hee Park, Keun Seok Lee, Sung Hoon Sim, Kyong-Hwa Park, Jee Hyun Kim, Byung Ho Nam, Hee-Jun Kim, Tae-Yong Kim, Kyung-Hun Lee, Sung-Bae Kim, Jin-Hee Ahn, Suee Lee, Jungsil Ro
Cancer Res Treat. 2019;51(1):43-52. Published online February 14, 2018
Purpose
We investigated whether irinotecan plus capecitabine improved progression-free survival (PFS) compared with capecitabine alone in patients with human epidermal growth factor 2 (HER2) negative and anthracycline and taxane pretreated metastatic breast cancer (MBC).
Materials and Methods
A total of 221 patients were randomly assigned to irinotecan (80 mg/m2, days 1 and 8) and capecitabine (1,000 mg/m2 twice a day, days 1-14) or capecitabine alone (1,250 mg/m2 twice a day, days 1-14) every 3 weeks. The primary endpoint was PFS.
Results
There was no significant difference in PFS between the combination and monotherapy arm (median, 6.4 months vs. 4.7 months; hazard ratio [HR], 0.84; 95% confidence interval [CI], 0.63 to 1.11; p=0.84). In patients with triple-negative breast cancer (TNBC, n=90), the combination significantly improved PFS (median, 4.7 months vs. 2.5 months; HR, 0.58; 95% CI, 0.37 to 0.91; p=0.02). Objective response rate was numerically higher in the combination arm, though it failed to reach statistical significance (44.4% vs. 33.3%, p=0.30). Overall survival did not differ between arms (median, 20.4 months vs. 24.0 months; p=0.63). While grade 3 or 4 neutropenia was more common in the combination arm (39.6% vs 9.0%), hand-foot syndrome was more often observed in capecitabine arm. Quality of life measurements in global health status was similar. However, patients in the combination arm showed significantly worse symptom scales especially in nausea/vomiting and diarrhea.
Conclusion
Irinotecan plus capecitabine did not prove clinically superior to single-agent capecitabine in anthracycline- and taxane-pretreated HER2 negative MBC patients. Toxicity profiles of the two groups differed but were manageable. The role of added irinotecan in patients with TNBC remains to be elucidated.
Citations
Citations to this article as recorded by
The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yu Cancer Research and Treatment.2025; 57(1): 39. CrossRef
Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence José Ángel García-Saenz, Álvaro Rodríguez-Lescure, Josefina Cruz, Joan Albanell, Emilio Alba, Antonio Llombart Targeted Oncology.2025;[Epub] CrossRef
Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer Cui-Cui Liu, Lie Chen, Yu-Wen Cai, Yu-Fei Chen, Yi-Ming Liu, Yu-Jie Zhou, Zhi-Ming Shao, Ke-Da Yu Cell Reports Medicine.2024; 5(2): 101396. CrossRef
Efficacy and safety of nanoparticle albumin‐bound paclitaxel in taxane‐pretreated metastatic breast cancer patients Weili Xiong, Ting Xu, Xiao Liu, Lili Zhang, Yuan Yuan Cancer.2024; 130(S8): 1488. CrossRef
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study Mengqian Ni, Lijia Zhou, Yongkui Lu, Dachuan Guo, Xiuyue Li, Lixia Li, Lidong Zhang, Meiting Chen, Lulu Zhang, Fei Xu, Zhongyu Yuan, Shusen Wang, Yanxia Shi, Anli Yang, Xin An BMC Cancer.2024;[Epub] CrossRef
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer Sara A. Hurvitz, Aditya Bardia, Kevin Punie, Kevin Kalinsky, Lisa A. Carey, Hope S. Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M. Tolaney npj Breast Cancer.2024;[Epub] CrossRef
A Dual Bispecific Hydrolysis Peptide‐Drug Conjugate Responsive to Micro‐Acidic and Reduction Circumstance Promotes Antitumor Efficacy in Triple‐Negative Breast Cancer Tingting Tang, Naiyu Liu, Lingjuan Wang, Kaiyue Zuo, Xinjie Zhu ChemBioChem.2024;[Epub] CrossRef
Synergizing Immunotherapy and Antibody–Drug Conjugates: New Horizons in Breast Cancer Therapy Antonello Pinto, Chiara Guarini, Marianna Giampaglia, Valeria Sanna, Assunta Melaccio, Laura Lanotte, Anna Natalizia Santoro, Francesca Pini, Antonio Cusmai, Francesco Giuliani, Gennaro Gadaleta-Caldarola, Palma Fedele Pharmaceutics.2024; 16(9): 1146. CrossRef
Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors Yoichi Naito, Seigo Nakamura, Nobuko Kawaguchi-Sakita, Takanori Ishida, Takahiro Nakayama, Yutaka Yamamoto, Norikazu Masuda, Koji Matsumoto, Takahiro Kogawa, Kazuki Sudo, Akihiko Shimomura, Catherine Lai, Danjie Zhang, Yuki Iwahori, Dianna Gary, Danh Huyn International Journal of Clinical Oncology.2024; 29(11): 1684. CrossRef
A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments Binghe Xu, Fei Ma, Tao Wang, Shusen Wang, Zhongsheng Tong, Wei Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, Weihong Zhao, Xiuyu Julie Cong, Jiongjie Chen International Journal of Cancer.2023; 152(10): 2134. CrossRef
Update on Classic and Novel Approaches in Metastatic Triple-Negative Breast Cancer Treatment: A Comprehensive Review Salvatore Greco, Nicolò Fabbri, Riccardo Spaggiari, Alfredo De Giorgi, Fabio Fabbian, Antonio Giovine Biomedicines.2023; 11(6): 1772. CrossRef
Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer Jiao Xie, SiNi Li, YaMin Li, JianHe Li BMC Health Services Research.2023;[Epub] CrossRef
Triple negative breast cancer: second and successive lines of treatment Fernando Henao Carrasco, Sara Leal Sánchez Revisiones en Cáncer.2023;[Epub] CrossRef
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer Rebecca A Dent, David W Cescon, Thomas Bachelot, Kyung Hae Jung, Zhi-Ming Shao, Shigehira Saji, Tiffany A Traina, Petra Vukovic, Darlington Mapiye, Micah J Maxwell, Peter Schmid, Javier Cortés Future Oncology.2023; 19(35): 2349. CrossRef
An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer Shao-Xian Cheng, Qiu-Chi Chen, Guo-He Lin, Yan-Hong Han, Bi-Cheng Wang, Yi Dai, Yan-Xia Zhao Medicine.2023; 102(30): e34486. CrossRef
Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database Wensheng Liu, Qiong Du, Zihan Guo, Xuan Ye, Jiyong Liu Frontiers in Pharmacology.2023;[Epub] CrossRef
Effects of Sacituzumab on Breast Cancer: Target Therapy Elina Armani Khatibi, Tooba Gholikhani, Balam Jimenez Brito, Nastaran Farshbaf Moghimi Biomedical Research Bulletin.2023; 1(4): 141. CrossRef
The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC Chris Twelves, Rupert Bartsch, Noa Efrat Ben-Baruch, Simona Borstnar, Luc Dirix, Petra Tesarova, Constanta Timcheva, Lyudmila Zhukova, Xavier Pivot Clinical Breast Cancer.2022; 22(3): 223. CrossRef
Quality-of-life methodology in hormone receptor–positive advanced breast cancer: Current tools and perspectives for the future Fatima Cardoso, David Cella, Galina Velikova, Victoria Harmer, Eva Schumacher-Wulf, Julie Rihani, Ana Casas, Nadia Harbeck Cancer Treatment Reviews.2022; 102: 102321. CrossRef
Comprehensive metabolomics expands precision medicine for triple-negative breast cancer Yi Xiao, Ding Ma, Yun-Song Yang, Fan Yang, Jia-Han Ding, Yue Gong, Lin Jiang, Li-Ping Ge, Song-Yang Wu, Qiang Yu, Qing Zhang, François Bertucci, Qiuzhuang Sun, Xin Hu, Da-Qiang Li, Zhi-Ming Shao, Yi-Zhou Jiang Cell Research.2022; 32(5): 477. CrossRef
Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival F. Miglietta, M. Bottosso, G. Griguolo, M.V. Dieci, V. Guarneri ESMO Open.2022; 7(2): 100409. CrossRef
Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class Joseph N. Samuel, Christopher M. Booth, Elizabeth Eisenhauer, Michael Brundage, Scott R. Berry, Bishal Gyawali JAMA Oncology.2022; 8(6): 879. CrossRef
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer Joyce O’Shaughnessy, Adam Brufsky, Hope S. Rugo, Sara M. Tolaney, Kevin Punie, Sagar Sardesai, Erika Hamilton, Delphine Loirat, Tiffany Traina, Roberto Leon-Ferre, Sara A. Hurvitz, Kevin Kalinsky, Aditya Bardia, Stephanie Henry, Ingrid Mayer, Yanni Zhu, S Breast Cancer Research and Treatment.2022; 195(2): 127. CrossRef
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis Lisa A. Carey, Delphine Loirat, Kevin Punie, Aditya Bardia, Véronique Diéras, Florence Dalenc, Jennifer R. Diamond, Christel Fontaine, Grace Wang, Hope S. Rugo, Sara A. Hurvitz, Kevin Kalinsky, Joyce O’Shaughnessy, Sibylle Loibl, Luca Gianni, Martine Picc npj Breast Cancer.2022;[Epub] CrossRef
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O’Shaughnessy, Javier Cortés, Véronique Diéras, Lisa A. Carey, Luca Gianni, Martine J. Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, npj Breast Cancer.2022;[Epub] CrossRef
Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial Dou-Dou Li, Zhong-hua Tao, Bi-Yun Wang, Lei-Ping Wang, Jun Cao, Xi-Chun Hu, Jian Zhang npj Breast Cancer.2022;[Epub] CrossRef
Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy Jiawei Shou, Fan Mo, Shanshan Zhang, Lantian Lu, Ning Han, Liang Liu, Min Qiu, Hongseng Li, Weidong Han, Dongying Ma, Xiaojie Guo, Qianpeng Guo, Qinxue Huang, Xiaomeng Zhang, Shengli Ye, Hongming Pan, Shuqing Chen, Yong Fang Frontiers in Immunology.2022;[Epub] CrossRef
A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer Min Yan, Peng Yuan, Quchang Ouyang, Ying Cheng, Guohui Han, Dewei Wang, Li Ran, Tao Sun, Da Zhao, Yuju Bai, Shun’e Yang, Xiaojia Wang, Rong Wu, Xiaohua Zeng, Herui Yao, Xuening Ji, Jun Jiang, Xiaohua Hu, Haifeng Lin, Liping Zheng, Zhitu Zhu, Wei Ge, Junla Therapeutic Advances in Medical Oncology.2022;[Epub] CrossRef
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase Jasgit C. Sachdev, Pamela Munster, Donald W. Northfelt, Hyo Sook Han, Cynthia Ma, Fiona Maxwell, Tiffany Wang, Bruce Belanger, Bin Zhang, Yan Moore, Arunthathi Thiagalingam, Carey Anders Breast Cancer Research and Treatment.2021; 185(3): 759. CrossRef
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Sagar D. Sardesai, Kevin Kalinsky, Amelia B. Zelnak, Robert Weaver, Tiffany Traina, Florence Dalenc, Philippe Aftimos, Filipa Lynce, Sami Diab, New England Journal of Medicine.2021; 384(16): 1529. CrossRef
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study Linda T. Vahdat, Peter Schmid, Andres Forero-Torres, Kimberly Blackwell, Melinda L. Telli, Michelle Melisko, Volker Möbus, Javier Cortes, Alberto J. Montero, Cynthia Ma, Rita Nanda, Gail S. Wright, Yi He, Thomas Hawthorne, Rebecca G. Bagley, Abdel-Baset H npj Breast Cancer.2021;[Epub] CrossRef
Occult triple negative male breast cancer. The usefulness of molecular platforms. A case report Angelats L, Estival A, Martinez-Cardús A, Musulen E, Margelí M Current Problems in Cancer: Case Reports.2021; : 100097. CrossRef
A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes Jiaojiao Suo, Xiaorong Zhong, Ping He, Hong Zheng, Tinglun Tian, Xi Yan, Ting Luo Frontiers in Oncology.2021;[Epub] CrossRef
Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies Ellen Cusano, Chelsea Wong, Eddy Taguedong, Marcus Vaska, Tasnima Abedin, Nancy Nixon, Safiya Karim, Patricia Tang, Daniel Y. C. Heng, Doreen Ezeife Current Oncology.2021; 28(6): 4894. CrossRef
High Antitumor Activity of the Dual Topoisomerase Inhibitor P8-D6 in Breast Cancer Inken Flörkemeier, Tamara N. Steinhauer, Nina Hedemann, Jörg Paul Weimer, Christoph Rogmans, Marion T. van Mackelenbergh, Nicolai Maass, Bernd Clement, Dirk O. Bauerschlag Cancers.2021; 14(1): 2. CrossRef
Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center Jennifer A. Weiss, Andrew Nicklawsky, Jodi A. Kagihara, Dexiang Gao, Christine Fisher, Anthony Elias, Virginia F. Borges, Peter Kabos, Sarah L. Davis, Stephen Leong, Sue Gail Eckhardt, Jennifer R. Diamond Cancer Medicine.2020; 9(23): 8801. CrossRef
Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer Vito Lorusso, Agnese Latorre, Francesco Giotta, Ozkan Kanat Journal of Oncology.2020; 2020: 1. CrossRef
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat, Sara M. Tolaney, Steven J. Isakoff, Jennifer R. Diamond, Joyce O’Shaughnessy, Rebecca L. Moroose, Alessandro D. Santin, Vandana G. Abramson, Nikita C. Shah, Hope S. Rugo, David M. Goldenberg, Ala M. Sweidan New England Journal of Medicine.2019; 380(8): 741. CrossRef
An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine I. Kümler, R. L. Eefsen, Peter Grundtvig Sørensen, S. Theile, A. Fullerton, P. G. Nielsen, Benny Vittrup Jensen, D. L. Nielsen Cancer Chemotherapy and Pharmacology.2019; 84(2): 441. CrossRef
Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy Burak Yasin Aktas, Gurkan Guner, Deniz Can Guven, Cagatay Arslan, Omer Dizdar Expert Review of Anticancer Therapy.2019; 19(7): 589. CrossRef
Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer Jennifer Weiss, Ashley Glode, Wells A. Messersmith, Jennifer Diamond Expert Review of Anticancer Therapy.2019; 19(8): 673. CrossRef
The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer I V Kolyadina, I V Poddubnaya Journal of Modern Oncology.2018; 20(3): 26. CrossRef
Purpose
Overexpression of cyclooxygenase 2 (COX-2) is thought to promote survival of transformed cells. Transforming growth factor β (TGF-β) exerts anti-proliferative effects on a broad range of epithelial cells. In the current study, we investigated whether TGF-β can regulate COX-2 expression in A549 human lung adenocarcinoma cells, which are TGF-β-responsive and overexpress COX-2.
Materials and Methods
Western blotting, Northern blotting, and mRNA stability assays were performed to demonstrate that COX-2 protein and mRNA expression were suppressed by TGF-β. We also evaluated the effects of tristetraprolin (TTP) on COX-2 mRNA using RNA interference.
Results
We demonstrated that COX-2 mRNA and protein expression were both significantly suppressed by TGF-β. An actinomycin D chase experiment demonstrated that COX-2 mRNA was more rapidly degraded in the presence of TGF-β, suggesting that TGF-β–induced inhibition of COX-2 expression is achieved via decreased mRNA stability. We also found that TGF-β rapidly and transiently induced the expression of TTP, a well-known mRNA destabilizing factor, before suppression of COX-2 mRNA expression was observed. Using RNA interference, we confirmed that increased TTP levels play a pivotal role in the destabilization of COX-2 mRNA by TGF-β. Furthermore, we showed that Smad3 is essential to TTP-dependent down-regulation of COX-2 expression in response to TGF-β.
Conclusion
The results of this study show that TGF-β down-regulated COX-2 expression via mRNA destabilization mediated by Smad3/TTP in A549 cells.
Citations
Citations to this article as recorded by
Milk: A Natural Guardian for the Gut Barrier Yanli Wang, Yiyao Gong, Muhammad Salman Farid, Changhui Zhao Journal of Agricultural and Food Chemistry.2024; 72(15): 8285. CrossRef
Tristetraprolin, a Potential Safeguard Against Carcinoma: Role in the Tumor Microenvironment Diwen Zhang, Zhigang Zhou, Ruixia Yang, Sujun Zhang, Bin Zhang, Yanxuan Tan, Lingyao Chen, Tao Li, Jian Tu Frontiers in Oncology.2021;[Epub] CrossRef
Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells Miso Lee, Kyung-Hun Lee, Ahrum Min, Jeongeun Kim, Seongyeong Kim, Hyemin Jang, Jee Min Lim, So Hyeon Kim, Dong-Hyeon Ha, Won Jae Jeong, Koung Jin Suh, Yae-Won Yang, Tae Yong Kim, Do-Youn Oh, Yung-Jue Bang, Seock-Ah Im Cancer Research and Treatment.2019; 51(2): 451. CrossRef
Transforming Growth Factor β Activation Primes Canonical Wnt Signaling Through Down‐Regulation of Axin‐2 Justin Gillespie, Rebecca L. Ross, Clarissa Corinaldesi, Filomena Esteves, Emma Derrett‐Smith, Michael F. McDermott, Gina M. Doody, Christopher P. Denton, Paul Emery, Francesco Del Galdo Arthritis & Rheumatology.2018; 70(6): 932. CrossRef
Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells Ahrum Min, Jung Eun Kim, Yu-Jin Kim, Jee Min Lim, Seongyeong Kim, Jin Won Kim, Kyung-Hun Lee, Tae-Yong Kim, Do-Youn Oh, Yung-Jue Bang, Seock-Ah Im Cancer Letters.2018; 430: 123. CrossRef
Identification of SMAD3 as a Novel Mediator of Inflammation in Human Myometrium In Vitro Martha Lappas Mediators of Inflammation.2018; 2018: 1. CrossRef
Tristetraprolin activation by resveratrol inhibits the proliferation and metastasis of colorectal cancer cells Se-Ra Lee, Hua Jin, Won-Tae Kim, Won-Jung Kim, Sung Zoo Kim, Sun-Hee Leem, Soo Mi Kim International Journal of Oncology.2018;[Epub] CrossRef
Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response Ahrum Min, Hyemin Jang, Seongyeong Kim, Kyung-Hun Lee, Debora Keunyoung Kim, Koung Jin Suh, Yaewon Yang, Paul Elvin, Mark J. O'Connor, Seock-Ah Im Molecular Cancer Therapeutics.2018; 17(12): 2507. CrossRef
Anti‐tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells Hee‐Jun Kim, Ahrum Min, Seock‐Ah Im, Hyemin Jang, Kyung Hun Lee, Alan Lau, Miso Lee, Seongyeong Kim, Yaewon Yang, Jungeun Kim, Tae Yong Kim, Do‐Youn Oh, Jeffrey Brown, Mark J. O'Connor, Yung‐Jue Bang International Journal of Cancer.2017; 140(1): 109. CrossRef
Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis Seongyeong Kim, Ahrum Min, Kyung-Hun Lee, Yaewon Yang, Tae-Yong Kim, Jee Min Lim, So Jung Park, Hyun-Jin Nam, Jung Eun Kim, Sang-Hyun Song, Sae-Won Han, Do-Youn Oh, Jee Hyun Kim, Tae-You Kim, David Hangauer, Johnson Yiu-Nam Lau, Kyongok Im, Dong Soon Lee, Cancer Research and Treatment.2017; 49(3): 643. CrossRef
AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells Ahrum Min, Seock-Ah Im, Hyemin Jang, Seongyeong Kim, Miso Lee, Debora Keunyoung Kim, Yaewon Yang, Hee-Jun Kim, Kyung-Hun Lee, Jin Won Kim, Tae-Yong Kim, Do-Youn Oh, Jeff Brown, Alan Lau, Mark J. O'Connor, Yung-Jue Bang Molecular Cancer Therapeutics.2017; 16(4): 566. CrossRef
HSP90 Inhibition Suppresses PGE2 Production via Modulating COX-2 and 15-PGDH Expression in HT-29 Colorectal Cancer Cells A. Mohammadi, M.M. Yaghoobi, A. Gholamhoseinian Najar, B. Kalantari-Khandani, H. Sharifi, M. Saravani Inflammation.2016;[Epub] CrossRef
Dysregulation of TTP and HuR plays an important role in cancers Hao Wang, Nannan Ding, Jian Guo, Jiazeng Xia, Yulan Ruan Tumor Biology.2016; 37(11): 14451. CrossRef
Low tristetraprolin expression promotes cell proliferation and predicts poor patients outcome in pancreatic cancer Zi-Ran Wei, Chao Liang, Dan Feng, Ya-Jun Cheng, Wei-Min Wang, De-Jun Yang, Yue-Xiang Wang, Qing-Ping Cai Oncotarget.2016; 7(14): 17737. CrossRef